Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents two postmenopausal women with frontal fibrosing alopecia whose hair loss stabilized after treatment with topical corticosteroids, one also using minoxidil.

This narrative review reports that metformin, traditionally used for type 2 diabetes management, may offer therapeutic benefits for various skin disorders, such as acne, rosacea, and psoriasis, due to its anti-inflammatory and other beneficial properties, warranting further exploration in dermatology.

Harris et al. describe a new mouse model for vitiligo, where interfollicular melanocytes are retained and melanocyte-targeting immune responses are simulated, aiding the development of immunomodulatory therapies.

This review discusses the causes, diagnosis, and treatment of pediatric alopecia, emphasizing early diagnosis and considering holistic approaches, but reports no new clinical results.

In this case study, a 13-year-old girl with multiple autoimmune symptoms was successfully treated with the antibiotic and immunomodulatory drug co-trimoxazole.

This review explores how molecular profiling in atopic dermatitis has led to new therapeutic developments, detailing approved and potential treatments, and discusses similar advances in alopecia areata; it reports no new results.

This review explores regenerative treatment options for non-scarring alopecia, with a focus on the potential of mesenchymal stem cells for hair regrowth, but it reports no new clinical results.

Salivary vitamin D and IL-6 could help diagnose and manage non-scarring alopecia.

This study found that sunscreen and moisturizer use was associated with a higher likelihood of developing frontal fibrosing alopecia in the reviewed studies.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

Hydroxychloroquine effectively treated twenty-nail dystrophy in a patient with alopecia areata.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

This review reported that certain systemic drugs, including antiepileptics and anticancer drugs, can lead to changes in hair pigmentation, such as hypopigmentation or hyperpigmentation, with varied prevalence and clinical characteristics.

This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.

This literature review highlights the effectiveness of topical vitamin D (e.g., calcipotriol, calcitriol) in treating vitiligo, emphasizing its role in melanogenesis and as an immunomodulator, either alone or combined with topical corticosteroids, offering minimal side effects.

This review summarizes recent research on the therapeutic uses of adipose-derived stem cells for wound healing and treating skin diseases but does not provide new experimental results.

This study found that electrospun membranes with aligned surface topography enhanced wound healing and hair follicle regeneration while modulating the immune response in a mouse skin wound model.

This review discusses the potential of mesenchymal stem cell therapies for treating various skin diseases, including vitiligo, alopecia, and epidermolysis bullosa, but reports no new results.

This study developed the TLMG hydrogel, a seamless in situ biointerface platform, demonstrating robust adhesion, high conductivity, and therapeutic effects for intelligent wound management in complex animal models and human tests, indicating its promise for integrated bioelectronic medicine.

This study suggests that cannabinoids, especially CBD, show promise as potential treatments for various inflammatory, infectious, and autoimmune skin diseases, with ongoing research needed to confirm clinical efficacy and safety.

This review of sequential immunotherapy strategies for alopecia areata suggests that combining initial intensive immunosuppression with maintenance therapy may effectively manage disease progression by modulating inflammation and restoring immune tolerance.

This study reviewed the expression of chemokines in patients with alopecia areata, finding elevated Th1 and Th2 chemokine levels, suggesting a complex immune profile that may require broad immunomodulatory strategies to address the disease's underlying immune dysregulation.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In a case report, complete hair regrowth was observed in a patient with severe alopecia areata after treatment with deucravacitinib, a TYK2 inhibitor, suggesting new therapeutic avenues for alopecia areata despite TYK2 not being traditionally linked to this condition.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This review discusses how ionizing radiation causes skin damage by inducing cellular senescence in keratinocytes, which secrete inflammatory mediators, recruiting immune cells and exacerbating inflammation, impacting the skin barrier function and healing.

This review highlights the promising therapeutic potential of Bacopa monnieri in treating various health conditions, particularly related to neuropharmacology, but emphasizes the need for further clinical research.

This article reviews treatments for alopecia areata, including corticosteroids and other immunomodulators, and reports no new experimental findings.

This article discusses various dermatological topics from the 2020 Dermatology Nurses' Association annual meeting held online, highlighting updates on skin conditions and treatments without reporting new clinical results.

This review explores the current treatments for different types of alopecia, emphasizing the need for well-designed clinical trials and highlighting that most therapies are used off-label, as only androgenetic alopecia has FDA-approved drugs.